Other languages Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-01 pm EDT			5-day change	1st Jan Change
0.65 ^USD	-1.53%		-1.07%	+91.06%

Apr. 16	Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct	MT
Apr. 16	Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	Apr. 16
Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients	Apr. 10
Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Monopar Therapeutics Inc. Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program	Mar. 05
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 22
Sector Update: Health Care	Feb. 22
Monopar Therapeutics Shares Rise on 'Promising' Preclinical Cancer Treatment Trial Results	Feb. 22
Top Midday Gainers	Feb. 22
Monopar Therapeutics Inc. Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers	Feb. 22
Sector Update: Health Care Stocks Softer Tuesday Afternoon	Feb. 20
Monopar Therapeutics Gets Clearance to Start Phase 1 Trial in Advanced Cancers in Australia	Feb. 20
Monopar Receives Clearance to Proceed with First-In-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers	Feb. 20
Monopar Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Investors Await Fed Decision as US Futures Move Lower in Wednesday's Premarket Activity	Nov. 01
Top Premarket Gainers	Nov. 01
Monopar Therapeutics Inc. Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society Annual Meeting	Nov. 01
Monopar Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Monopar Therapeutics Reports Positive Clinical Data From Camsirubicin Therapy Trial	23-08-08
Monopar Therapeutics Inc. Provides Update on Camsirubicin Clinical Trial	23-08-08
Monopar Therapeutics, National University of Singapore Enter Cancer Research Collaboration	23-07-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Other languages

Filters